Continuous Versus Intermittent Infusion of Furosemide in Acute Decompensated Heart Failure

Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although loop diuretics are used in nearly all patients with ADHF to relieve congestive symptoms, optimal dosing strategies remain poorly defined. Th...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of cardiac failure Ročník 16; číslo 3; s. 188 - 193
Hlavní autori: Thomson, Margaret R., Nappi, Jean M., Dunn, Steven P., Hollis, Ian B., Rodgers, Jo E., Van Bakel, Adrian B.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Elsevier Inc 01.03.2010
Predmet:
ISSN:1071-9164, 1532-8414, 1532-8414
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although loop diuretics are used in nearly all patients with ADHF to relieve congestive symptoms, optimal dosing strategies remain poorly defined. This was a prospective, randomized, parallel-group study comparing the effectiveness of continuous intravenous (cIV) with intermittent intravenous (iIV) infusion of furosemide in 56 patients with ADHF. The dose and duration of furosemide as well as concomitant medications to treat ADHF were determined by physician preference. The primary end point of the study was net urine output (nUOP)/24hours. Safety measures including electrolyte loss and hemodynamic instability were also assessed. Twenty-six patients received cIV and 30 patients received iIV dosing. The mean nUOP/24hours was 2098±1132mL in patients receiving cIV versus 1575±1100mL in the iIV group (P=.086). The cIV group had significantly greater total urine output (tUOP) with 3726±1121mL/24hours versus 2955±1267mL/24hours in the iIV group (P=.019) and tUOP/mg furosemide with 38.0±31.0mL/mg versus 22.2±12.5mL/mg (P=.021). Mean weight loss was not significantly different between the groups. The cIV group experienced a shorter length of hospital stay (6.9±3.7 versus 10.9±8.3 days, P=.006). There were no differences in safety measures between the groups. The cIV of furosemide was well tolerated and significantly more effective than iIV for tUOP. In addition, continuous infusion appears to provide more efficient diuresis.
AbstractList Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although loop diuretics are used in nearly all patients with ADHF to relieve congestive symptoms, optimal dosing strategies remain poorly defined. This was a prospective, randomized, parallel-group study comparing the effectiveness of continuous intravenous (cIV) with intermittent intravenous (iIV) infusion of furosemide in 56 patients with ADHF. The dose and duration of furosemide as well as concomitant medications to treat ADHF were determined by physician preference. The primary end point of the study was net urine output (nUOP)/24hours. Safety measures including electrolyte loss and hemodynamic instability were also assessed. Twenty-six patients received cIV and 30 patients received iIV dosing. The mean nUOP/24hours was 2098±1132mL in patients receiving cIV versus 1575±1100mL in the iIV group (P=.086). The cIV group had significantly greater total urine output (tUOP) with 3726±1121mL/24hours versus 2955±1267mL/24hours in the iIV group (P=.019) and tUOP/mg furosemide with 38.0±31.0mL/mg versus 22.2±12.5mL/mg (P=.021). Mean weight loss was not significantly different between the groups. The cIV group experienced a shorter length of hospital stay (6.9±3.7 versus 10.9±8.3 days, P=.006). There were no differences in safety measures between the groups. The cIV of furosemide was well tolerated and significantly more effective than iIV for tUOP. In addition, continuous infusion appears to provide more efficient diuresis.
Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although loop diuretics are used in nearly all patients with ADHF to relieve congestive symptoms, optimal dosing strategies remain poorly defined.BACKGROUNDDespite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although loop diuretics are used in nearly all patients with ADHF to relieve congestive symptoms, optimal dosing strategies remain poorly defined.This was a prospective, randomized, parallel-group study comparing the effectiveness of continuous intravenous (cIV) with intermittent intravenous (iIV) infusion of furosemide in 56 patients with ADHF. The dose and duration of furosemide as well as concomitant medications to treat ADHF were determined by physician preference. The primary end point of the study was net urine output (nUOP)/24 hours. Safety measures including electrolyte loss and hemodynamic instability were also assessed. Twenty-six patients received cIV and 30 patients received iIV dosing. The mean nUOP/24 hours was 2098+/-1132 mL in patients receiving cIV versus 1575+/-1100 mL in the iIV group (P=.086). The cIV group had significantly greater total urine output (tUOP) with 3726+/-1121 mL/24 hours versus 2955+/-1267 mL/24 hours in the iIV group (P=.019) and tUOP/mg furosemide with 38.0+/-31.0 mL/mg versus 22.2+/-12.5 mL/mg (P=.021). Mean weight loss was not significantly different between the groups. The cIV group experienced a shorter length of hospital stay (6.9+/-3.7 versus 10.9+/-8.3 days, P=.006). There were no differences in safety measures between the groups.METHODS AND RESULTSThis was a prospective, randomized, parallel-group study comparing the effectiveness of continuous intravenous (cIV) with intermittent intravenous (iIV) infusion of furosemide in 56 patients with ADHF. The dose and duration of furosemide as well as concomitant medications to treat ADHF were determined by physician preference. The primary end point of the study was net urine output (nUOP)/24 hours. Safety measures including electrolyte loss and hemodynamic instability were also assessed. Twenty-six patients received cIV and 30 patients received iIV dosing. The mean nUOP/24 hours was 2098+/-1132 mL in patients receiving cIV versus 1575+/-1100 mL in the iIV group (P=.086). The cIV group had significantly greater total urine output (tUOP) with 3726+/-1121 mL/24 hours versus 2955+/-1267 mL/24 hours in the iIV group (P=.019) and tUOP/mg furosemide with 38.0+/-31.0 mL/mg versus 22.2+/-12.5 mL/mg (P=.021). Mean weight loss was not significantly different between the groups. The cIV group experienced a shorter length of hospital stay (6.9+/-3.7 versus 10.9+/-8.3 days, P=.006). There were no differences in safety measures between the groups.The cIV of furosemide was well tolerated and significantly more effective than iIV for tUOP. In addition, continuous infusion appears to provide more efficient diuresis.CONCLUSIONSThe cIV of furosemide was well tolerated and significantly more effective than iIV for tUOP. In addition, continuous infusion appears to provide more efficient diuresis.
Abstract Background Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although loop diuretics are used in nearly all patients with ADHF to relieve congestive symptoms, optimal dosing strategies remain poorly defined. Methods and Results This was a prospective, randomized, parallel-group study comparing the effectiveness of continuous intravenous (cIV) with intermittent intravenous (iIV) infusion of furosemide in 56 patients with ADHF. The dose and duration of furosemide as well as concomitant medications to treat ADHF were determined by physician preference. The primary end point of the study was net urine output (nUOP)/24 hours. Safety measures including electrolyte loss and hemodynamic instability were also assessed. Twenty-six patients received cIV and 30 patients received iIV dosing. The mean nUOP/24 hours was 2098 ± 1132 mL in patients receiving cIV versus 1575 ± 1100 mL in the iIV group ( P = .086). The cIV group had significantly greater total urine output (tUOP) with 3726 ± 1121 mL/24 hours versus 2955 ± 1267 mL/24 hours in the iIV group ( P = .019) and tUOP/mg furosemide with 38.0 ± 31.0 mL/mg versus 22.2 ± 12.5 mL/mg ( P = .021). Mean weight loss was not significantly different between the groups. The cIV group experienced a shorter length of hospital stay (6.9 ± 3.7 versus 10.9 ± 8.3 days, P = .006). There were no differences in safety measures between the groups. Conclusions The cIV of furosemide was well tolerated and significantly more effective than iIV for tUOP. In addition, continuous infusion appears to provide more efficient diuresis.
Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although loop diuretics are used in nearly all patients with ADHF to relieve congestive symptoms, optimal dosing strategies remain poorly defined. This was a prospective, randomized, parallel-group study comparing the effectiveness of continuous intravenous (cIV) with intermittent intravenous (iIV) infusion of furosemide in 56 patients with ADHF. The dose and duration of furosemide as well as concomitant medications to treat ADHF were determined by physician preference. The primary end point of the study was net urine output (nUOP)/24 hours. Safety measures including electrolyte loss and hemodynamic instability were also assessed. Twenty-six patients received cIV and 30 patients received iIV dosing. The mean nUOP/24 hours was 2098+/-1132 mL in patients receiving cIV versus 1575+/-1100 mL in the iIV group (P=.086). The cIV group had significantly greater total urine output (tUOP) with 3726+/-1121 mL/24 hours versus 2955+/-1267 mL/24 hours in the iIV group (P=.019) and tUOP/mg furosemide with 38.0+/-31.0 mL/mg versus 22.2+/-12.5 mL/mg (P=.021). Mean weight loss was not significantly different between the groups. The cIV group experienced a shorter length of hospital stay (6.9+/-3.7 versus 10.9+/-8.3 days, P=.006). There were no differences in safety measures between the groups. The cIV of furosemide was well tolerated and significantly more effective than iIV for tUOP. In addition, continuous infusion appears to provide more efficient diuresis.
Author Nappi, Jean M.
Dunn, Steven P.
Hollis, Ian B.
Rodgers, Jo E.
Van Bakel, Adrian B.
Thomson, Margaret R.
Author_xml – sequence: 1
  givenname: Margaret R.
  surname: Thomson
  fullname: Thomson, Margaret R.
  organization: Baptist Hospital, Saint Thomas Health Services, Nashville, TN
– sequence: 2
  givenname: Jean M.
  surname: Nappi
  fullname: Nappi, Jean M.
  organization: South Carolina College of Pharmacy, Charleston, SC
– sequence: 3
  givenname: Steven P.
  surname: Dunn
  fullname: Dunn, Steven P.
  organization: University of Kentucky Chandler Medical Center, Lexington, KY
– sequence: 4
  givenname: Ian B.
  surname: Hollis
  fullname: Hollis, Ian B.
  organization: University of North Carolina, School of Pharmacy and Hospitals, Chapel Hill, NC
– sequence: 5
  givenname: Jo E.
  surname: Rodgers
  fullname: Rodgers, Jo E.
  organization: University of North Carolina, School of Pharmacy and Hospitals, Chapel Hill, NC
– sequence: 6
  givenname: Adrian B.
  surname: Van Bakel
  fullname: Van Bakel, Adrian B.
  email: vanbakel@musc.edUTH
  organization: Medical University of South Carolina, Charleston, SC
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20206891$$D View this record in MEDLINE/PubMed
BookMark eNqNkstqHDEQRUVwiO1JfsH0Lqtul_otCCFmkrENhizyWGQj1FIJNOmWJnoE_PdRM3YWXsRZVRXce6k60jk5sc4iIRcUKgq0v9xXUnilhZmrGoBVlFYA3QtyRrumLseWtie5h4GWjPbtKTkPYQ8AYwvDK3JaQw39yOgZ-bF1NhqbXArFd_Qhl1sb0S8mRrQxDzoF42zhdLFL3gVcjMLC2OJKpojFR5RuOaANIqIqblD4WOzyVsnja_JSizngm4e6Id92n75ub8q7z9e326u7UrbDEEsGHUMt9aTyOOlOI4xyFC1F1ahatRIGwSbBpKCsGbuu77tpaoamZZNmw6SaDXl7zD149ythiHwxQeI8C4v5LD40De1GyJYNuXhQpmlBxQ_eLMLf80ccWdAfBTJfGjzqvxIKfOXO9_yRO1-5c0p55p6N754YpYkiZnDRr9pn7R-Odsycfhv0PEiDVqIyHmXkypnnI94_iZCzsUaK-SfeY9i75G1-BU55qDnwL-vfWL8GMKC5Yf8O-J8N_gAlas3x
CitedBy_id crossref_primary_10_1161_CIR_0b013e3181f9a223
crossref_primary_10_1016_j_tvjl_2018_07_001
crossref_primary_10_1016_j_mcna_2012_07_003
crossref_primary_10_1080_21548331_2021_1893065
crossref_primary_10_1093_ajhp_zxae059
crossref_primary_10_1177_0269216311399490
crossref_primary_10_1007_s11936_012_0186_5
crossref_primary_10_1371_journal_pone_0196088
crossref_primary_10_1056_NEJMoa1005419
crossref_primary_10_1016_j_repce_2014_08_018
crossref_primary_10_1590_1806_9282_20220583
crossref_primary_10_1111_anae_14038
crossref_primary_10_1002_ehf2_13286
crossref_primary_10_1016_j_ahj_2010_09_014
crossref_primary_10_1080_10826076_2012_712931
crossref_primary_10_1007_s10741_018_9727_7
crossref_primary_10_1159_000529068
crossref_primary_10_1177_2050312120940094
crossref_primary_10_1016_j_repc_2014_08_019
crossref_primary_10_1097_CNQ_0000000000000173
crossref_primary_10_1002_phar_1369
crossref_primary_10_1007_s00392_019_01521_y
crossref_primary_10_1177_039493621202400120
crossref_primary_10_1016_j_amjms_2022_12_013
crossref_primary_10_1136_spcare_2022_003863
crossref_primary_10_2146_ajhp150023
crossref_primary_10_1016_j_mayocp_2014_01_004
crossref_primary_10_1016_j_cardfail_2019_11_013
crossref_primary_10_1097_MD_0000000000025669
crossref_primary_10_1007_s10557_013_6491_8
crossref_primary_10_1007_s10741_012_9354_7
crossref_primary_10_1177_0897190016645435
crossref_primary_10_1002_phar_1798
crossref_primary_10_1016_j_repc_2022_05_012
crossref_primary_10_1097_ACO_0b013e328347b491
crossref_primary_10_1007_s11897_012_0094_8
crossref_primary_10_1097_PCC_0000000000000303
crossref_primary_10_1007_s11739_014_1112_5
crossref_primary_10_1038_nrcardio_2014_215
crossref_primary_10_1016_j_jchf_2018_04_008
crossref_primary_10_1016_j_ehj_2017_12_005
crossref_primary_10_1016_j_cardfail_2017_06_008
crossref_primary_10_1177_0885066616669494
crossref_primary_10_7759_cureus_34758
crossref_primary_10_1097_ACO_0b013e3283462257
crossref_primary_10_1186_s43054_023_00225_3
crossref_primary_10_1186_cc13952
crossref_primary_10_1053_j_ajkd_2011_06_005
crossref_primary_10_1177_1074248413482755
crossref_primary_10_1002_jhm_991
crossref_primary_10_1016_j_jcrc_2013_10_009
crossref_primary_10_1155_2022_4627826
crossref_primary_10_1007_s11886_016_0801_2
crossref_primary_10_1177_1074248412446194
crossref_primary_10_1016_j_ihj_2014_03_006
crossref_primary_10_1016_j_jcrc_2013_03_015
crossref_primary_10_1002_ehf2_14168
crossref_primary_10_5049_EBP_2015_13_1_17
Cites_doi 10.3109/00365519709099409
10.1038/ki.1989.246
10.1161/CIRCHEARTFAILURE.108.821785
10.1016/j.cardfail.2005.11.017
10.1159/000047397
10.1345/aph.1G693
10.1016/0002-9610(83)90344-6
10.1016/0735-1097(96)00161-1
10.1016/S0022-3565(25)21252-6
10.1378/chest.102.3.725
10.1016/S0735-1097(03)00765-4
10.1002/14651858.CD003178.pub3
10.1002/j.1552-4604.1996.tb04197.x
ContentType Journal Article
Copyright 2010 Elsevier Inc.
Elsevier Inc.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2010 Elsevier Inc.
– notice: Elsevier Inc.
– notice: Copyright (c) 2010 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.cardfail.2009.11.005
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-8414
EndPage 193
ExternalDocumentID 20206891
10_1016_j_cardfail_2009_11_005
S1071916409011919
1_s2_0_S1071916409011919
Genre Randomized Controlled Trial
Journal Article
Comparative Study
GroupedDBID ---
--K
--M
-RU
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DU5
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEB
HMK
HMO
HVGLF
HX~
HZ~
IHE
J1W
KOM
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OA~
OL0
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SDF
SDG
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
UHS
WUQ
Z5R
~G-
~HD
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
9DU
AAYXX
CITATION
AGCQF
AGRNS
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c477t-9059efcfbd477bf5fe08c8a41ed3d2d4c07a9ba9ca193855665bb37349bf97bd3
ISICitedReferencesCount 66
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000277582100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1071-9164
1532-8414
IngestDate Mon Sep 29 06:42:45 EDT 2025
Mon Jul 21 06:04:05 EDT 2025
Sat Nov 29 07:06:08 EST 2025
Tue Nov 18 21:46:54 EST 2025
Sun Apr 06 06:54:29 EDT 2025
Sun Feb 23 10:19:17 EST 2025
Tue Oct 14 19:31:40 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Diuretics
furosemide
heart failure
Language English
License Copyright (c) 2010 Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c477t-9059efcfbd477bf5fe08c8a41ed3d2d4c07a9ba9ca193855665bb37349bf97bd3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
PMID 20206891
PQID 733158037
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_733158037
pubmed_primary_20206891
crossref_primary_10_1016_j_cardfail_2009_11_005
crossref_citationtrail_10_1016_j_cardfail_2009_11_005
elsevier_sciencedirect_doi_10_1016_j_cardfail_2009_11_005
elsevier_clinicalkeyesjournals_1_s2_0_S1071916409011919
elsevier_clinicalkey_doi_10_1016_j_cardfail_2009_11_005
PublicationCentury 2000
PublicationDate 2010-03-01
PublicationDateYYYYMMDD 2010-03-01
PublicationDate_xml – month: 03
  year: 2010
  text: 2010-03-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of cardiac failure
PublicationTitleAlternate J Card Fail
PublicationYear 2010
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Kramer, Smith, Ferguson, Serpas, Grant, Black (bib15) 1996; 36
Fonarow (bib2) 2003; 4
Domanski, Norman, Pitt, Haigney, Hanlon, Peyster (bib3) 2003; 42
Aaser, Gullestad, Tollofsrud, Lundberg, Hall, Djoseland (bib16) 1997; 57
Ellison (bib10) 2001; 96
Hammarlund, Odlind, Paalzow (bib11) 1985; 233
Lahav, Regev, Ra'anani, Theodor (bib13) 1992; 102
Dormans, VanMeyel, Gerlag, Tan, Russel, Smiths (bib7) 1996; 28
Felker, O'Connor, Braunwald (bib9) 2009; 2
American Heart Association, American Stroke Association. Heart disease and stroke statistics—2008 update. Available from
Salvador DRK, Rey NR, Ramos GC, Punzalan FER. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD003178. DOI: 10.1002/14651858.CD003178.pub3
(bib4) 2006; 12
Gulbis, Spencer (bib6) 2006; 40
Pivac, Rumboldt, Sardelic, Bagatin, Polic, Ljutic (bib14) 1998
Loon, Wilcox, Unwin (bib12) 1989; 36
Accessed December 11, 2009.
Copeland, Campbell, Rlachetka, Salomon, Larson (bib5) 1983; 146
Copeland (10.1016/j.cardfail.2009.11.005_bib5) 1983; 146
Loon (10.1016/j.cardfail.2009.11.005_bib12) 1989; 36
Pivac (10.1016/j.cardfail.2009.11.005_bib14) 1998
Kramer (10.1016/j.cardfail.2009.11.005_bib15) 1996; 36
Dormans (10.1016/j.cardfail.2009.11.005_bib7) 1996; 28
Domanski (10.1016/j.cardfail.2009.11.005_bib3) 2003; 42
Gulbis (10.1016/j.cardfail.2009.11.005_bib6) 2006; 40
10.1016/j.cardfail.2009.11.005_bib8
Fonarow (10.1016/j.cardfail.2009.11.005_bib2) 2003; 4
(10.1016/j.cardfail.2009.11.005_bib4) 2006; 12
Felker (10.1016/j.cardfail.2009.11.005_bib9) 2009; 2
Ellison (10.1016/j.cardfail.2009.11.005_bib10) 2001; 96
Aaser (10.1016/j.cardfail.2009.11.005_bib16) 1997; 57
Hammarlund (10.1016/j.cardfail.2009.11.005_bib11) 1985; 233
Lahav (10.1016/j.cardfail.2009.11.005_bib13) 1992; 102
10.1016/j.cardfail.2009.11.005_bib1
References_xml – reference: Salvador DRK, Rey NR, Ramos GC, Punzalan FER. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD003178. DOI: 10.1002/14651858.CD003178.pub3
– reference: . Accessed December 11, 2009.
– volume: 4
  start-page: S21
  year: 2003
  end-page: S30
  ident: bib2
  article-title: Acute Decompensated Heart Failure National Registry (ADHERE) Advisory Committee. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure
  publication-title: Rev Cardiovasc Med
– volume: 102
  start-page: 725
  year: 1992
  end-page: 731
  ident: bib13
  article-title: Intermittent administration of furosemide versus continuous infusion preceded by a loading dose for congestive heart failure
  publication-title: Chest
– volume: 146
  start-page: 796
  year: 1983
  end-page: 799
  ident: bib5
  article-title: Diuresis with continuous infusion of furosemide after cardiac surgery
  publication-title: Am J Surg
– volume: 96
  start-page: 132
  year: 2001
  end-page: 143
  ident: bib10
  article-title: Diuretic therapy and resistance in congestive heart failure
  publication-title: Cardiology
– volume: 233
  start-page: 447
  year: 1985
  end-page: 453
  ident: bib11
  article-title: Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling
  publication-title: J Pharmacol Exp Ther
– volume: 36
  start-page: 265
  year: 1996
  end-page: 270
  ident: bib15
  article-title: Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion with congestive heart failure
  publication-title: J Clin Pharm
– volume: 12
  start-page: e86
  year: 2006
  end-page: 103
  ident: bib4
  article-title: Evaluation and management of patients with acute decompensated heart failure
  publication-title: J Card Fail
– volume: 42
  start-page: 705
  year: 2003
  end-page: 708
  ident: bib3
  article-title: Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD)
  publication-title: J Am Coll Cardiol
– start-page: 121
  year: 1998
  end-page: 128
  ident: bib14
  article-title: Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure
  publication-title: Int J Clin Pharm Res
– volume: 36
  start-page: 682
  year: 1989
  end-page: 689
  ident: bib12
  article-title: Mechanism of impaired natriuretic response to furosemide during prolonged therapy
  publication-title: Kidney Intl
– volume: 2
  start-page: 56
  year: 2009
  end-page: 62
  ident: bib9
  article-title: Loop diuretics in acute decompensated heart failure, necessary? evil?, a necessary evil?
  publication-title: Circ Heart Fail
– volume: 40
  start-page: 1797
  year: 2006
  end-page: 1803
  ident: bib6
  article-title: Efficacy and safety of a furosemide continuous infusion following cardiac surgery
  publication-title: Ann Pharmacother
– volume: 57
  start-page: 361
  year: 1997
  end-page: 368
  ident: bib16
  article-title: Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure
  publication-title: Scand J Clin Lab Invest
– volume: 28
  start-page: 376
  year: 1996
  end-page: 382
  ident: bib7
  article-title: Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion
  publication-title: J Am Coll Cardiol
– reference: American Heart Association, American Stroke Association. Heart disease and stroke statistics—2008 update. Available from:
– volume: 57
  start-page: 361
  year: 1997
  ident: 10.1016/j.cardfail.2009.11.005_bib16
  article-title: Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure
  publication-title: Scand J Clin Lab Invest
  doi: 10.3109/00365519709099409
– volume: 36
  start-page: 682
  year: 1989
  ident: 10.1016/j.cardfail.2009.11.005_bib12
  article-title: Mechanism of impaired natriuretic response to furosemide during prolonged therapy
  publication-title: Kidney Intl
  doi: 10.1038/ki.1989.246
– volume: 2
  start-page: 56
  year: 2009
  ident: 10.1016/j.cardfail.2009.11.005_bib9
  article-title: Loop diuretics in acute decompensated heart failure, necessary? evil?, a necessary evil?
  publication-title: Circ Heart Fail
  doi: 10.1161/CIRCHEARTFAILURE.108.821785
– volume: 12
  start-page: e86
  year: 2006
  ident: 10.1016/j.cardfail.2009.11.005_bib4
  article-title: Evaluation and management of patients with acute decompensated heart failure
  publication-title: J Card Fail
  doi: 10.1016/j.cardfail.2005.11.017
– volume: 96
  start-page: 132
  year: 2001
  ident: 10.1016/j.cardfail.2009.11.005_bib10
  article-title: Diuretic therapy and resistance in congestive heart failure
  publication-title: Cardiology
  doi: 10.1159/000047397
– volume: 40
  start-page: 1797
  year: 2006
  ident: 10.1016/j.cardfail.2009.11.005_bib6
  article-title: Efficacy and safety of a furosemide continuous infusion following cardiac surgery
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.1G693
– volume: 146
  start-page: 796
  year: 1983
  ident: 10.1016/j.cardfail.2009.11.005_bib5
  article-title: Diuresis with continuous infusion of furosemide after cardiac surgery
  publication-title: Am J Surg
  doi: 10.1016/0002-9610(83)90344-6
– volume: 28
  start-page: 376
  year: 1996
  ident: 10.1016/j.cardfail.2009.11.005_bib7
  article-title: Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion
  publication-title: J Am Coll Cardiol
  doi: 10.1016/0735-1097(96)00161-1
– volume: 233
  start-page: 447
  year: 1985
  ident: 10.1016/j.cardfail.2009.11.005_bib11
  article-title: Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)21252-6
– volume: 102
  start-page: 725
  year: 1992
  ident: 10.1016/j.cardfail.2009.11.005_bib13
  article-title: Intermittent administration of furosemide versus continuous infusion preceded by a loading dose for congestive heart failure
  publication-title: Chest
  doi: 10.1378/chest.102.3.725
– ident: 10.1016/j.cardfail.2009.11.005_bib1
– volume: 42
  start-page: 705
  year: 2003
  ident: 10.1016/j.cardfail.2009.11.005_bib3
  article-title: Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD)
  publication-title: J Am Coll Cardiol
  doi: 10.1016/S0735-1097(03)00765-4
– volume: 4
  start-page: S21
  issue: Suppl 7
  year: 2003
  ident: 10.1016/j.cardfail.2009.11.005_bib2
  article-title: Acute Decompensated Heart Failure National Registry (ADHERE) Advisory Committee. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure
  publication-title: Rev Cardiovasc Med
– start-page: 121
  year: 1998
  ident: 10.1016/j.cardfail.2009.11.005_bib14
  article-title: Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure
  publication-title: Int J Clin Pharm Res
– ident: 10.1016/j.cardfail.2009.11.005_bib8
  doi: 10.1002/14651858.CD003178.pub3
– volume: 36
  start-page: 265
  year: 1996
  ident: 10.1016/j.cardfail.2009.11.005_bib15
  article-title: Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion with congestive heart failure
  publication-title: J Clin Pharm
  doi: 10.1002/j.1552-4604.1996.tb04197.x
SSID ssj0008407
Score 2.1926427
Snippet Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF) remain high. Although...
Abstract Background Despite advances in the treatment of chronic ambulatory heart failure, hospitalization rates for acute decompensated heart failure (ADHF)...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 188
SubjectTerms Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Cardiovascular
Chi-Square Distribution
Diuretics
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
furosemide
Furosemide - administration & dosage
Furosemide - adverse effects
heart failure
Heart Failure - diagnosis
Heart Failure - drug therapy
Humans
Infusions, Intravenous - methods
Injections, Intravenous - methods
Male
Middle Aged
Probability
Prospective Studies
Risk Assessment
Severity of Illness Index
Sodium Potassium Chloride Symporter Inhibitors - administration & dosage
Sodium Potassium Chloride Symporter Inhibitors - adverse effects
Treatment Outcome
Young Adult
Title Continuous Versus Intermittent Infusion of Furosemide in Acute Decompensated Heart Failure
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1071916409011919
https://www.clinicalkey.es/playcontent/1-s2.0-S1071916409011919
https://dx.doi.org/10.1016/j.cardfail.2009.11.005
https://www.ncbi.nlm.nih.gov/pubmed/20206891
https://www.proquest.com/docview/733158037
Volume 16
WOSCitedRecordID wos000277582100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: ScienceDirect
  customDbUrl:
  eissn: 1532-8414
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0008407
  issn: 1071-9164
  databaseCode: AIEXJ
  dateStart: 19950301
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtswECWcpCh6Kbqm7hLw0JuhlFpoikfXseF0MYI2LYxeBIoSAQW2YlhykF_vrUORtB0kTtMAvXgRSJmeeZoZksM3CL0nRHYFZamnSSe9SBHuCV8IT0Yi65JUiG7DePPzCxuP48mEn7Rav91ZmIspK8v48pLP_6uq4RooWx-d_Qd1r24KF-AzKB1eQe3weifFa76polzq1Fa9GAZvzarfrKhrve9_XKplZaPEoeayzGdF1jCH9KTOGTjKdZY5TG6FjkVHIJ26MxTF1DKP3BDIygZksqM2WtlUE3ucy1XT7Xw7NIs4YjE7apDVX1e4Hov5vDAJN3oD6ZaWLug2Fdk6J7c0HWnOcWMI4aYft7W0yx56x97lfVlLDbERWGpDgb4y5d0NyIYbdtk3tQOti_dNUcZr3sMsZJwdarlpmRk6U03ySujaX7ocgUH_s-9VwSHxvuvB6LEQfZCXWx9wlcbbT6ogIcm1pjtoL2CUg0_Z6x0PJp9WYQTMvJlJmDX_c-N4-80j3BZZbZs5NRHU6RP02CIG9wxkn6JWXj5DD7_a5I7n6NcaudggF28iFzvk4nOF18jFRYkb5OIryMUNcrFF7gv0Yzg47Y88W_oDjARjtcch6s-VVGkGX1NFVU5iGYvIz7MwC7JIEiZ4KrgUoMuYwpyEpmnIwoinirM0C1-i3fK8zF8hTAMqFc1VqiSJFI05IyoLIiapkFz5pI2oE1siLS--Ls8yTVwC5FnixK2LtnKYNCcg7jb6sOo3N8wwf-3BnFYSd-4ZPHUC8Ltfz7yydqdKtsGrjfiqp42pTax8p1_FDjoJOB29kyjKHECQ6EKvNCYha6N9A6mVCAKYf3Zj7r--95DfoEfrB_4t2q0Xy_wdeiAv6qJaHKAdNokP7MPyB94fAqg
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Continuous+Versus+Intermittent+Infusion+of+Furosemide+in+Acute+Decompensated+Heart+Failure&rft.jtitle=Journal+of+cardiac+failure&rft.au=Thomson%2C+Margaret+R.%2C+PharmD%2C+BCPS&rft.au=Nappi%2C+Jean+M.%2C+PharmD%2C+BCPS&rft.au=Dunn%2C+Steven+P.%2C+PharmD%2C+BCPS&rft.au=Hollis%2C+Ian+B.%2C+PharmD%2C+BCPS&rft.date=2010-03-01&rft.issn=1071-9164&rft.volume=16&rft.issue=3&rft.spage=188&rft.epage=193&rft_id=info:doi/10.1016%2Fj.cardfail.2009.11.005&rft.externalDBID=ECK1-s2.0-S1071916409011919&rft.externalDocID=1_s2_0_S1071916409011919
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10719164%2FS1071916410X00033%2Fcov150h.gif